Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt Ratio (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Debt Ratio for 5 consecutive years, with 1.1 as the latest value for Q2 2022.

  • On a quarterly basis, Debt Ratio rose 23.38% to 1.1 in Q2 2022 year-over-year; TTM through Jun 2022 was 1.1, a 23.38% increase, with the full-year FY2020 number at 0.84, up 49.18% from a year prior.
  • Debt Ratio was 1.1 for Q2 2022 at Theravance Biopharma, down from 1.11 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 1.11 in Q1 2022 to a low of 0.41 in Q4 2018.
  • A 5-year average of 0.74 and a median of 0.71 in 2020 define the central range for Debt Ratio.
  • Peak YoY movement for Debt Ratio: soared 67.0% in 2021, then rose 7.29% in 2022.
  • Theravance Biopharma's Debt Ratio stood at 0.41 in 2018, then surged by 36.81% to 0.56 in 2019, then surged by 49.18% to 0.84 in 2020, then rose by 15.14% to 0.96 in 2021, then increased by 14.05% to 1.1 in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Debt Ratio are 1.1 (Q2 2022), 1.11 (Q1 2022), and 0.96 (Q3 2021).